Savara (SVRA) Operating Income (2010 - 2026)
Savara (SVRA) reported Operating Income of -$39.0 million for Q1 2026, down 37.12% year-over-year from -$62.0 million in Q1 2025, and down 16.67% on a QoQ basis from -$33.4 million in Q4 2025.
Savara (SVRA) has 17 years of Operating Income data on file, last reported at -$39.0 million in Q1 2026.
- Quarterly Operating Income fell 37.12% year-over-year to -$39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$134.1 million (down 22.86% YoY) and the FY2025 annual result came in at -$123.5 million, down 19.72% from the prior year.
- Operating Income retreated to -$39.0 million in Q1 2026 per SVRA's latest filing, from -$33.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$8.0 million in Q1 2022 and bottomed at -$39.0 million in Q1 2026.
- The 5-year median for Operating Income is -$22.5 million (2024), against an average of -$21.4 million.
- The widest annual swing landed in 2022, when Operating Income increased 22.74%; it then slumped 89.76% in 2024.
- Tracing SVRA's Operating Income over 5 years: stood at -$10.9 million in 2022, then slumped by 62.11% to -$17.6 million in 2023, then sank by 76.82% to -$31.2 million in 2024, then retreated by 7.2% to -$33.4 million in 2025, then retreated by 16.67% to -$39.0 million in 2026.
- Per Business Quant, the three latest SVRA Operating Income figures stand at -$39.0 million (Q1 2026), -$33.4 million (Q4 2025), and -$30.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | -38.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.99 Mn |
| Dec 31, 2025 | -33.42 Mn |
| Sep 30, 2025 | -30.26 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -28.44 Mn |
| Dec 31, 2024 | -31.17 Mn |
| Sep 30, 2024 | -26.36 Mn |
| Jun 30, 2024 | -23.19 Mn |
| Mar 31, 2024 | -22.48 Mn |
| Dec 31, 2023 | -17.63 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -12.22 Mn |
| Mar 31, 2023 | -12.11 Mn |
| Dec 31, 2022 | -10.88 Mn |
| Sep 30, 2022 | -10.54 Mn |
| Jun 30, 2022 | -9.38 Mn |
| Mar 31, 2022 | -8.05 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -9.97 Mn |
| Jun 30, 2021 | -10.45 Mn |
| Mar 31, 2021 | -10.41 Mn |
| Dec 31, 2020 | -13.01 Mn |
| Sep 30, 2020 | -10.79 Mn |
| Jun 30, 2020 | -9.26 Mn |
| Mar 31, 2020 | -16.24 Mn |
| Dec 31, 2019 | -31.51 Mn |
| Sep 30, 2019 | -12.44 Mn |
| Jun 30, 2019 | -22.15 Mn |
| Mar 31, 2019 | -12.92 Mn |
| Dec 31, 2018 | -13.25 Mn |
| Sep 30, 2018 | -12.78 Mn |
| Jun 30, 2018 | -11.91 Mn |
| Mar 31, 2018 | -32.11 Mn |
| Dec 31, 2017 | -9.30 Mn |
| Sep 30, 2017 | -6.54 Mn |
| Jun 30, 2017 | -9.34 Mn |
| Mar 31, 2017 | -4.77 Mn |
| Dec 31, 2016 | -4.04 Mn |
| Sep 30, 2016 | -3.23 Mn |
| Jun 30, 2016 | -1.98 Mn |
| Mar 31, 2016 | -1.69 Mn |
| Dec 31, 2015 | -9.71 Mn |
| Sep 30, 2015 | -9.83 Mn |
| Jun 30, 2015 | -10.18 Mn |
| Mar 31, 2015 | -9.65 Mn |
| Dec 31, 2014 | -7.35 Mn |
| Sep 30, 2014 | -7.88 Mn |
| Jun 30, 2014 | -7.20 Mn |
| Mar 31, 2014 | -6.84 Mn |
| Dec 31, 2013 | -5.72 Mn |
| Sep 30, 2013 | -5.27 Mn |
| Jun 30, 2013 | -4.95 Mn |
| Mar 31, 2013 | -5.59 Mn |
| Dec 31, 2012 | -4.02 Mn |
| Sep 30, 2012 | -3.22 Mn |
| Jun 30, 2012 | -4.22 Mn |
| Mar 31, 2012 | -4.17 Mn |
| Dec 31, 2011 | -2.44 Mn |
| Sep 30, 2011 | -3.55 Mn |
| Jun 30, 2011 | -4.41 Mn |
| Mar 31, 2011 | -2.99 Mn |
| Dec 31, 2010 | -2.31 Mn |
| Sep 30, 2010 | -1.87 Mn |
| Jun 30, 2010 | -1.94 Mn |